Zytiga
J&J to pay up to $1 billion in Aragon deal
June 18, 2013Research and Development, Sales and Marketing Aragon, J&J, JJ, Zytiga
Johnson & Johnson could pay as much as $1 billion to buy prostate cancer specialist Aragon Pharmaceuticals. The acquisition includes …
Prostate cancer drug Xtandi gets nod
April 26, 2013Sales and Marketing Xtandi, Zytiga, prostate cancer
Astellas and Medivation have received a positive opinion from Europe’s Committee for Medicinal Products for Human Use (CHMP) for Xtandi, …
Zytiga extended in EU
January 15, 2013Sales and Marketing EU, J&J, JJ, Janssen, Zytiga
Janssen is celebrating the European Commission’s decision to extend the licence for its prostate cancer treatment Zytiga. The once-daily pill …
New J&J chief still struggling with scandals
July 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alex Gorsky, J&J, JJ, Risperdal, Weldon, Xarelto, Zytiga
Johnson & Johnson has just released its Q2 figures showing sales fell back in the second quarter, a 3.5% growth …
Astellas submits new prostate cancer drug to EMA
June 28, 2012Research and Development, Sales and Marketing Astellas, EMA, Medivation, NICE, Zytiga, enzalutamide
Astellas has submitted its investigational prostate cancer drug enzalutamide to the European Medicines Agency. Enzalutamide is a once-daily pill that works …
NICE final yes for Zytiga and Tarceva
June 27, 2012Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga
In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …
Janssen looks to broaden Zytiga licence
June 18, 2012Sales and Marketing Cancer, Janssen, NICE, Provenge, Zytiga, prostate
Janssen is looking to broaden the licence for its prostate cancer pill Zytiga. Zytiga currently has a US and European …
Price cut sways NICE on Zytiga
May 16, 2012Sales and Marketing Jevtana, NICE, Zytiga, prostate cancer
NICE is recommending Janssen’s prostate cancer pill Zytiga, reversing its previous stance. In its final guidance, the watchdog is recommending …
NICE recommends Xgeva for bone metastasis
March 29, 2012Sales and Marketing Amgen, NICE, Xgeva, Zytiga, denosumab, prostate cancer
NICE has issued draft guidance recommending Amgen’s Xgeva (denosumab) for certain groups of cancer patients whose disease has spread to …
Prostate cancer drug extends life after chemotherapy
March 29, 2012Research and Development, Sales and Marketing Astellas, Medivation, Zytiga, prostate cancer
Prostate cancer treatment MDV3100 has been shown to extend life by nearly five months in men with advanced disease who …
Charity attacks Scottish decision on Zytiga
March 14, 2012Sales and Marketing Janssen, NICE, PAS, Prostate Cancer Charity, Zytiga
Scotland’s medicines regulator has turned down Janssen’s prostate cancer pill Zytiga, leading to a backlash from charities. The Scottish Medicines …
Strong Zytiga study results could increase uptake
March 12, 2012Research and Development, Sales and Marketing IDMC, Janssen, Provenge, Zytiga, prostate
Janssen’s prostate cancer pill Zytiga could be on course to target a larger number of patients following a positive late-stage …
Cancer Drugs Fund should not be used across the UK
March 7, 2012Sales and Marketing CDF, Janssen, NICE, Zytiga, myloma, prostate
The Prostate Cancer Charity has said that extending England’s Cancer Drugs Fund to the UK will not solve the issue …
Zytiga approved in Wales – for now
February 21, 2012Sales and Marketing AWMSG, CDF, Janssen, NICE, Wales, Zytiga
Janssen’s cancer treatment Zytiga has been approved in Wales, in contrast to its rejection by NICE. The All Wales Medicines …
Zytiga cost too high, says NICE
February 2, 2012Sales and Marketing NICE, Zytiga
NICE is not recommending Janssen’s prostate cancer pill Zytiga because of its high cost. Zytiga (abiraterone) is not recommended, in …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
